Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(17%)
Results Posted
150%(3 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
2
33%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
Terminated1
unknown1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

terminated117%
completed233%
unknown117%
withdrawn117%
active_not_recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
active_not_recruitingphase_1

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

NCT04158739
completedphase_1

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

NCT04681105
completedphase_1

Post-transplant Flotetuzumab for AML

NCT05506956
terminatedphase_2

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

NCT04582864
unknown

Flotetuzumab Expanded Access Program

NCT04678466
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04158739Phase 1

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

Active Not Recruiting
NCT04681105Phase 1

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Completed
NCT05506956Phase 1

Post-transplant Flotetuzumab for AML

Completed
NCT04582864Phase 2

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Terminated
NCT04678466

Flotetuzumab Expanded Access Program

Unknown
NCT05063123Phase 2

Study to Assess an Interphase Cycle With Flotetuzumab.

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6